ABSTRACT. Objectives. Type B Niemann-Pick disease (NPD-B) caused by acid sphingomyelinase deficiency is a rare, autosomal recessive, lysosomal storage disorder with a broad range of disease severity. The objectives of this study were to document the natural history of the disease in a large, clinically heterogeneous patient population that was followed for a period of 10 years and to determine how genotype influences phenotype.
N iemann-Pick disease (NPD) is a lysosomal storage disease caused by deficient activity of acid sphingomyelinase (ASM; sphingomyelin phosphodiesterase; EC 3.1.4.12) and the accumulation of sphingomyelin within cells of the monocyte-macrophage system. 1 Types A and B NPD are inherited as autosomal recessive traits and result from allelic mutations in the ASM gene. Type A disease (NPD-A), which has an Ashkenazi Jewish predilection, is a fatal neurodegenerative disorder of infancy. In contrast, type B NPD (NPD-B), which is panethnic, is a nonneuronopathic disease characterized by hepatosplenomegaly, hyperlipidemia, and pulmonary involvement, with most patients living into adulthood. Other, more variable features of NPD-B may include liver dysfunction, cardiac disease, retinal stigmata, and growth retardation. [2] [3] [4] [5] [6] There is a broad spectrum of disease manifestations among NPD-B patients, ranging from onset in childhood with massive organomegaly, secondary hypersplenism, growth restriction, and later pulmonary involvement or liver failure to a milder, attenuated course. As in other lysosomal storage diseases, this marked phenotypic variability is influenced by genotype, 7, 8 although other factors such as gender and age may also contribute to disease severity. To date, the phenotypic variability and the delineation of genotype/phenotype correlations have been limited to single case descriptions or reports of small series of patients, rather than detailed longitudinal studies. This lack of information about the natural history of NPD-B makes it difficult not only to provide prognostic information to patients and families but also to evaluate potential therapeutic interventions, such as enzyme replacement therapy.
We now report the results of a 10-year longitudinal study of the phenotypic heterogeneity of NPD-B. In addition, we describe the natural history of NPD-Brelated hematologic disease, hyperlipidemia, pulmonary involvement, and liver dysfunction and compare disease progression with age, gender, and genotype.
METHODS

Study Patients
Twenty-nine patients with NPD-B (15 male, 14 female; age range at entry: 2.2-64.1 years) from 23 unrelated families were evaluated. At entry, 20 patients were in the pediatric age group (Ͻ18 years old) and 9 were adults (Ͼ18 years old). Two patients had undergone splenectomy before entry into the study, and 1 had undergone a bone marrow transplantation but had lost the graft and continued to display disease manifestations. One patient was started on statin therapy at age 29. One splenectomized patient required oxygen at 61 years of age, and a nonsplenectomized patient required oxygen at night starting at 11 years of age. Of the 23 families, 20 were of mixed European/white descent, 1 was of Yemeni descent, and 2 were Ashkenazi Jewish.
Each patient had Ն2 visits to the Mount Sinai General Clinical Research Center at least 9 months apart (mean number of visits: 4.3; range: 2-13) between 1992 and 2002. The length of time from initial to final visit ranged from 1 to 10 years (mean: 4.3 years). The study was approved by the Mount Sinai School of Medicine Institutional Review Board. Voluntary, written informed consent was obtained from each patient or guardian, and minor assent was obtained from children who were Ͼ6 years old before any studyrelated procedures. The diagnosis of NPD-B was confirmed in each patient by the demonstration of reduced ASM activity in isolated leukocytes and/or cultured skin fibroblasts and by the identification of 2 disease-causing ASM mutations.
Clinical Studies
Medical histories and physical examinations were performed at each visit. The standard deviation and z score for the most recent height and weight were determined using the Epi Info 2000 Program (Version 1.1.2, Centers for Disease Control and Prevention, Atlanta, GA, www.cdc.gov/epiinfo/ei2000.htm; data not shown). At the first visit, quantitative computed tomography scans were performed on 23 patients to measure liver and spleen volumes. At each visit, blood was drawn for laboratory analyses, including serum alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin, complete blood count, and lipid profile. Pulmonary function tests (PFTs) were performed in accordance with the current guidelines, 9 using a SensorMedics 6200 Autobox DL (Yorba Linda, CA). Diffusion capacity for carbon monoxide (DLCO) was measured using the single-breath method, which was corrected for hemoglobin levels.
Determination of Genotype
Dot-blot hybridization using allele-specific oligonucleotides was used to screen for the previously identified common mutations in the ASM gene (R496L, L302P, fsP330, and ⌬R608). In patients with unidentified mutations, sequencing of the entire ASM gene was performed as previously described. 10, 11 Putative mutations were confirmed by dot-blot hybridization or endonuclease digestion of polymerase chain reaction-amplified genomic DNA from the proband and family members.
Determination of Phenotypic Severity Score and Genotype/Phenotype Correlations
To evaluate the relationship between phenotype and genotype, we assigned phenotypic severity scores. Spleen and liver size, platelet count, high-density lipoprotein (HDL) cholesterol concentration, pediatric growth restriction, and adult pulmonary disease were used to determine overall phenotypic severity. Scores were given for each variable, ranging from mild (score ϭ 1: spleen volume 1-5 multiples of normal [MN] ; liver volume 1-1.25 MN; platelet count Ͼ150 ϫ 10 3 per mm 3 , HDL cholesterol Ͼ35 mg/dL) to severe (score ϭ 4: spleen volume Ͼ15.1 MN; liver volume Ͼ1.76 MN; platelet count Ͻ49 ϫ 10 3 per mm 3 ; HDL cholesterol Ͻ14 mg/dL). For patients who were Ͻ18 years old, growth restriction was graded from 1 (mild: height z score between 0 and Ϫ1) to 3 (severe: height z score ϽϪ2.1). Patients who were Ͼ18 years old and did not have pulmonary signs were given a score of 1, those with cyanosis or clubbing were given a score of 2, and those with oxygen dependence were given a score of 3. The sum of the scores from each category was the overall phenotypic severity score, which was categorized as mild (overall score 6 -11), moderate (overall score [12] [13] [14] or severe (overall score Ͼ15).
Statistical Analysis
To evaluate the initial value for hematologic indices, lipid profile, lung function, and lipids, we used multiple regression (or equivalently 2-way analysis of variance) with variables age group (Ͻ18 or Ͼ18) and gender. This allowed us to give mean values for age group adjusted by gender and the reverse.
The definitive analysis of changes over time was performed by fitting a straight line to each patient's data using a random intercept model using PROC MIXED of SAS. (We also tried random slope and intercept model and other variants but on the basis of these results found no evidence that these more complicated models were helpful.) This analysis allows for arbitrary number of observations per patient over time. The method gives an estimate of the annual change, which gives more weight to patients with a longer follow-up and many visits than to patients with a shorter follow-up and few visits. In addition, we compared the percentage of final and initial values that were outside the normal range using McNemar test.
RESULTS
Hepatosplenomegaly and Hematologic Indices
Spleen volumes ranged from 4.5 to 27.3 MN, with a mean of 12.7 MN. The mean liver volume was 1.91 MN (range: 0.93-3.21 MN). Two patients who had undergone splenectomy were excluded from the analyses of the hematologic values, because the abnormalities arise from hypersplenism.
The adjusted mean leukocyte count and hemoglobin concentration were lower in patients who were Ͻ18 years old, whereas the adjusted mean platelet count was lower in patients who were Ͼ18 years old (Fig 1) . No significant gender disparities were found for the hematologic indices. At the final visit, significantly more patients had abnormal values for leukocyte count and platelet count (34% and 54%, respectively) than at the initial visit (3% and 39%, respectively; Table 1 ). Analogously, mean annual Initial values for patients who were Ͻ18 years old (■) versus patients who were Ͼ18 years old (u), adjusted for gender. Units for each parameter are as shown in Table 1 . Values for direct bilirubin (DB) and total bilirubin (TB) were multiplied by 100.
rates of change for leukocytes and platelet counts were Ϫ0.19 ϫ 10 3 per mm 3 (P ϭ .001) and Ϫ6.84 ϫ 10 3 per mm 3 (P Ͻ .001), respectively, predicting a gradual worsening over time for both. Figure 2 shows the gradual decline in these indices in a patient who had a severe phenotype and was followed for the longest time.
Lipid Abnormalities
Most patients had borderline to high total and low-density lipoprotein (LDL) cholesterol, low HDL cholesterol, and borderline to high triglycerides at the initial visit (Table 1) , with the adults having worse initial values than children (Fig 1) . Male patients had higher triglycerides and lower HDL cholesterol than female patients at the first visit (triglycerides: 336.1 mg/dL vs 229.6 mg/dL, P ϭ .04; HDL cholesterol: 14.3 mg/dL vs 24.7 mg/dL, P ϭ .047). Evaluation of the estimated annual change showed statistically significant improvement for HDL and triglycerides with yearly changes of 0.47 mg/dL (P ϭ .004) and Ϫ7.37 mg/dL (P Ͻ .001), respectively. Cor- Percentages respondingly, the percentage of patients with values outside the normal range declined significantly for triglycerides, with a change from 83% abnormal at baseline to 68% abnormal at last visit (P Ͻ .05). In contrast, the percentage of patients with abnormal values did not change for HDL cholesterol. The improvement in total cholesterol was of borderline significance on the basis of estimated annual change. The results were inconclusive for LDL, with the most sensitive statistical method showing a small, nonsignificant improvement and the generally cruder analysis examining percentage with abnormal readings showing a significant deterioration.
Pulmonary Studies
More than one third of patients had abnormal forced expiratory volume at 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC values on entry into the study (Table 1 ). In addition, more than two thirds of the patients had a low DLCO at the initial visit. At the initial visit, mean values for FEV1, FVC, FEV1/FVC, DLCO, and total lung capacity (TLC) were higher in patients who were Ͻ18 years old and lower in patients who were Ͼ18 years old (Fig 1) . These differences for the last 3 outcomes were statistically significant for FEV1/FVC, DLCO, and TLC. For FEV1/FVC, DLCO, and TLC, the respective P values were .001, .02, and .004. Estimated mean annual changes were negative for all measures of pulmonary function (Table 1) , and this deterioration was statistically significant for FEV1 (P ϭ .014) and FEV1/FVC (P Ͻ .001) with estimated annual mean changes of Ϫ1.6% predicted and Ϫ0.7% predicted, respectively.
Liver Function
At the initial visit, there were no significant differences in liver function with respect to gender or age (Fig 1) , with the exception of total bilirubin, which was higher in patients who were Ͼ18 years old (P ϭ .01). Similarly, no statistically significant changes in liver function, whether viewed on the basis of mean change over time or of percentage of patients with abnormalities, were noted (Table 1) . Both transaminases tended to remain elevated in most patients throughout the study. All patients had normal bilirubin values throughout the study. One patient developed hepatic dysfunction ϳ2 years after his last visit and subsequently died of liver failure.
Genotype-Phenotype Correlations
The 29 patients in the study had 23 different genotypes (Table 2) . Eight patients had a mild phenotype, 11 had a moderate phenotype, and 10 had a severe phenotype. The genotypes that were associated with those phenotypic severity categories are shown in Table 2 . As has been previously reported, individuals who were homozygous for ⌬R608 had a milder disease phenotype. In addition, patients who were homozygous for P323A and P330R had less severe disease than patients with all other genotypes.
Mortality Among Study Patients
One patient died of liver failure in his early 10s, another died of a traumatic subdural hematoma at 9 years of age, and a third died at 18 years from long-term complications after a failed bone marrow transplant.
DISCUSSION
The results of this study provide the first data on the natural history of the disease manifestations in NPD-B. The NPD-B phenotype, which displays a broad range of phenotypic severity, included hepatosplenomegaly with secondary hypersplenism, an atherogenic lipid profile, abnormal pulmonary function, and mild liver dysfunction.
The natural history of the hematologic complications was characterized by decreasing leukocyte and platelet counts with age, whereas the hemoglobin concentration remained stable. Presumably, the decreasing cell counts result from progressive hypersplenism. The clinical consequences of the progressive leukopenia and thrombocytopenia of particular importance to NPD-B patients include infection, particularly of the respiratory tract, and bleeding episodes, respectively.
The majority of patients studied had an atherogenic lipid profile characterized by low HDL cholesterol, high total and LDL cholesterol, and high triglycerides. The finding that HDL cholesterol is decreased at all ages is concerning because this is a major risk factor for coronary artery disease and studies are continuing to assess the clinical consequences of this profile. Although the total cholesterol, LDL cholesterol, and triglycerides may be amenable to dietary modifications and exercise, these interventions may not be possible in more severely affected NPD-B patients because of growth restriction and pulmonary disease, and transaminases have been noted to increase markedly in some affected patients after administration of statins (M.M.M, unpublished observations), which thus might be contraindicated. Therefore, the treatment of the lipid abnormalities in NPD-B is problematic. The pulmonary function tests revealed a restrictive pattern of lung involvement with abnormal diffusing capacity, compatible with interstitial lung disease. The progressive nature of the pulmonary involvement is supported by the consistent findings that (1) older patients have lower mean PFT values than younger patients, (2) the number of patients with abnormal PFT values increased with time, and (3) the calculated mean annual change was negative for all measures of pulmonary function. Although many NPD-B patients are asymptomatic, more severely affected patients may exhibit cough, shortness of breath, and recurrent respiratory infections. 12 Cyanosis, clubbing, rales, and rhonchi may be present on physical examination in such patients. The typical chest radiograph has interstitial infiltrates with reticulonodular changes and areas of ground glass density, often out of proportion to clinical manifestations. 13 Studies in ASM knockout mice, which have histopathologic and clinical changes similar to human NPD-B patients, 14 reveal that inflammation, abnormal surfactant catabolism, and abnormal surfactant composition all contribute to lung abnormalities. 15 However, more detailed studies of lung function are required to understand better the pathophysiology of the pulmonary disease in NPD-B.
The evaluation of liver function revealed mild elevations of serum transaminase activities and bilirubin concentrations. Although none of the patients whom we studied underwent liver biopsy as part of the clinical protocol, several had had biopsies before entry to the study. In these patients and in other reports form the literature, biopsy specimens show vacuolated, lipid-laden cells with or without fibrosis. 16 In addition, several cases of severe liver disease have been reported in patients with NPD-B, ranging from children with fatal hepatic failure 17 to adults with cirrhosis and portal hypertension. 2 These clinical descriptions, coupled with the findings on pathologic examination of the liver, raise concerns about the ultimate contribution of liver dysfunction to the morbidity and mortality of NPD-B patients. Serum transaminases were abnormal in most patients and tended not to change significantly over time. Our results raise the question of whether these measurements of liver function are adequate to assess the full range of liver disease in patients with NPD-B. Physical stigmata and radiographic findings may be more helpful in ascertaining the extent and ultimate prognosis of the liver involvement.
Many ASM mutations have been identified in unrelated NPD-B patients, [18] [19] [20] and a single common mutation, ⌬R608, has been described. 21, 22 Because of the number of private mutations and the rarity of this disease, a phenotypic severity score was used to correlate phenotype with genotype. Mild disease was associated with homozygosity for missense mutations such as ⌬R608, P323A, and P330R. Patients who were compound heterozygotes for ⌬R608 and a different mutation, however, tended to have either moderate or severe disease, suggesting that these other missense mutations, namely H567L, P475L, R496L, R441X, R600H, W391G, and H425K, are more deleterious.
CONCLUSIONS
Serial evaluations of 29 patients with NPD-B provided information on the natural history of the disease. Leukopenia and thrombocytopenia tended to worsen over time, and the atherogenic lipid profile tended to remain markedly abnormal despite some normalization of the triglyceride level. In addition, pulmonary function gradually worsened, and serum transaminases remained elevated. Unfortunately, many features of this progressive disease are not amenable to any available therapies. It therefore is hoped that future efforts directed at correcting the underlying metabolic abnormality, such as enzyme replacement or gene therapy, may prove effective at treating the hematologic, lipid, pulmonary, and hepatic abnormalities in this disorder.
